Name: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients by Citeline
Duration: 34 min 18 s
Description: Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

The European Commission has put forward a series of proposals designed to simplify European Union sustainability rules and boost the region’s competitiveness. As a result, application dates for EU due diligence and sustainability reporting requirements have been delayed by two years. Other proposals such as reducing the frequency of reporting and narrowing the scope of supply chains are still subject to trilogue negotiation. In the first of two Over the Counter episodes, CEN Group director Jasper Crone returns to the podcast to explain what might change, where he thinks this is all coming from and why companies should consider getting ready for new sustainability reporting rules even if they are no longer directly affected. 

Timestamps:
2:00 – Introductions
4:30 – EU sustainability reporting regulation recap
7:20 – Omnibus simplification package
12:00 – Simplification, or confusion?
19:00 – Where’s this all coming from?
23:30 – Why sustainability reporting is still good for business
25:40 – What’s all this got to do with competitiveness?

Guest Bio:
Jasper Crone is a Director at CEN-ESG, a corporate sustainability consultancy which helps businesses maximise their corporate sustainability potential, improving performance and ESG disclosure.
Crone leads on several client teams, covering the implementation of internal controls and sustainability data, setting sustainability and net zero targets and developing programmes for implementation and operationalisation of objectives.
He is experienced in sustainability reporting and the CEN-ESG assists clients with all aspects of sustainability reporting, whether regulatory, investor or customer driven. He brings a range of skills from 20 years of experience in the financial markets, in both the investment banking and investment management industries. He has a BSc in Biology from University of Bristol and is a CFA charter holder.
You can contact Jasper via email: jasper@cen-esg.com

Unpacking EU Omnibus And Its Impact On Sustainability: With CEN Group’s Jasper Crone

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

관세와 무역 장벽의 출현, 정책 변화 등으로 올해 유럽 바이오기업들의 자금조달이 쉽지 않은 상황이라는 In Vivo 기사를 요약한 내용입니다.
https://insights.citeline.com/in-vivo/market-intelligence/the-360-degrees-of-european-biotech-financing-in-2025-KZUNCOS3GZAYLBPGFTLJUBY7SY/

Join Seoul-based Scrip and Pink Sheet editor Jung Won Shin in this Korean-language mini podcast on recent biopharma industry topics. 

Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

 

 

 

유럽 바이오기업, 자금조달의 현주소는? (Korean-language podcast)

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 20, 2025. In this episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project. 
https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-VYWYRS37HJH6HNRZJHNGCWVSNM/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - June 23, 2025

The race for new therapies is more intense than ever. This episode uncovers how biotech and pharma use competitive intelligence, AI, and data to outsmart rivals and change the game.

Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella, and Claire Riches, VP of Clinical Solutions at Citeline, a leading provider of life sciences data and insights.

View the video series and find out more information here: https://www.citeline.com/biotech

Staying True: Finding Your Edge in a Crowded Field [Biotech Under Pressure in 2025]

The FDA’s Diversity Action Plan guidance underwent several changes in recent months—with the draft guidance taken down, restored, and then pulled again—creating uncertainty for sponsors planning Phase III and pivotal trials across all therapeutic areas. With the final guidance expected by June 26, CRO regulatory leaders reflected on how companies can manage this evolving environment. They explored:

The impact of the FDA’s changing Diversity Action Plan guidance on sponsors’ trial planning
How companies adapted strategies to maintain inclusivity goals amid shifting regulatory priorities
Broader implications for trial design, pipeline strategies, and sponsor approaches in the global drug development landscape
 
This episode is part 2 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we’ll continue exploring the key forces shaping the future of clinical trials.

Listen to part 1 here: https://insights.citeline.com/scrip/partnered-content/podcast-series-navigating-regulatory-changes-market-dynamics-cro-perspectives-on-the-future-of-clinical-trials-26Q4Q35N6BHTZGLHIKHK6V2NXY/

Navigating Regulatory Uncertainty: Diversity Action Plans

Join Scrip editors Mandy Jackson and Mary Jo Laffler and Pink Sheet editor Sarah Karlin-Smith as they discuss the general mood at the recent BIO International Convention in Boston and around the current US economic and biopharma policy environment in general, along with other key topics at BIO including vaccines, deal and financing and the rise of China's innovation. 
https://insights.citeline.com/scrip/conferences/bio/post-bio-podcast-thoughts-from-the-frontlines-ID7TBPASUFG4HKFSH56TK44DUM/

https://insights.citeline.com/pink-sheet/conferences/bio/post-bio-podcast-thoughts-from-the-frontlines-VGDKPJ2QQRBV5B6TY36ROPKE4Q/

Time stamps

(0:45) Economic and policy environment in the US
(2:50) BIO leadership surprisingly open about the industry’s challenges, and willingness to call out Trump government
(4:20) Most-favored nation policy proposal: storm in a teacup or existential threat
(7:57) DTC sales: new opportunities to sidestep middlemen? GLP-1s leading the way
(10:52) Impact of FDA staff cuts and changes on regulatory practices and policy, and on biopharma companies
(16:47) Reaction of vaccine companies, health providers, insurers and other stakeholders to ACIP panel dismissal and policy uncertainty
(22:27) Climate for biopharma dealmaking and financing; demand for assets
(27:28) Advice for startups in challenging times
(29:49) China’s biopharma industry in the ascendant
(33:27) Rare diseases policy, regulation and industry focus
(38:15) Priorities for BIO

Post-BIO Podcast: Thoughts From The Frontlines

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 27, 2025. In this episode: top drugs in the first quarter; deal trends at bio; Novo and Lilly’s obesity segmentation plans; Chinese firms at ADA; and five drugs that surpassed sales expectations.  
https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-H57S2YTFQRBOLACVOV5SLXWK3Y/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - June 30, 2025

With growing FDA bottlenecks and regulatory changes, this episode explores how biotechs are looking beyond borders by rethinking trials, embracing real-world data, and  finding new global pathways to bring therapies to life.

Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella, and Claire Riches, VP of Clinical Solutions at Citeline, a leading provider of life sciences data and insights.

View the video series and find out more information here: https://www.citeline.com/biotech


Weathering the Storm: Love, Laws, and Global Trials [FDA Regulations & Biotech in 2025]

Summer Colling and Emma Wille speak with oncology experts Nkiru Ibeanu, Neha Anand, Anna Simmons and David Dahan about the 2025 American Society of Clinical Oncology (ASCO) conference. Deeper coverage is available through Datamonitor Healthcare

Datamonitor Healthcare Podcast: ASCO 2025

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

Citeline

Related tracks